Skip to main content
MedPathMedPath Home
Clinical Trials/EUCTR2006-000763-29-LT
EUCTR2006-000763-29-LT
Active, not recruiting
Not Applicable

Pharmacokinetics, pharmacodynamics and safety of intra-articular multiple doses of 500 mcg icatibant in an uncontrolled 13-week multi-center study in patients with symptomatic knee osteoarthritis - TRICAPEKA

Sanofi-Aventis Deutschland GmbH0 sites12 target enrollmentApril 13, 2006
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Not specified
Sponsor
Sanofi-Aventis Deutschland GmbH
Enrollment
12
Status
Active, not recruiting
Last Updated
14 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
April 13, 2006
End Date
TBD
Last Updated
14 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • •Male and female subjects with painful osteoarthritis of the knee
  • •Are the trial subjects under 18? no
  • •Number of subjects for this age range:
  • •F.1\.2 Adults (18\-64 years) yes
  • •F.1\.2\.1 Number of subjects for this age range
  • •F.1\.3 Elderly (\>\=65 years) yes
  • •F.1\.3\.1 Number of subjects for this age range

Exclusion Criteria

  • •\- Subjects with knee OA of Kellgren \& Lawrence grade \< II
  • •\- Age \< 18 years
  • •\- Diagnosis of OA \< 3 months (based on the 1986 American College of Rheumatology (ACR) diagnostic criteria
  • •\- History of inflammatory or infectious joint disease of an origin other than OA
  • •\- Acute major trauma
  • •\- Existence of a relevant pain problem at localizations other than the target knee joint (e.g., migraine, low back pain etc., but also bilateral symptomatic knee OA)

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Not Applicable
Pharmacokinetics, pharmacodynamics and safety of a new Leuprolide acetate 22.5 mg depot formulation, when given as palliative treatment to prostate cancer patientsProstate cancerMedDRA version: 8.1Level: LLTClassification code 10007113Term: Cancer of prostate
EUCTR2006-005964-24-GBItalfarmaco S.p.A.20
Withdrawn
Not Applicable
Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Oral Doses of the Arginase Inhibitor INCB001158 (formerly known as CB-1158) as a Single Agent and in Combination with Immune Checkpoint Therapy in Patients with Advanced/Metastatic Solid Tumors
NL-OMON48697Incyte Corporation12
Active, not recruiting
Phase 1
Pharmacokinetic and pharmacodynamic evaluation of linezolid administered intravenously in MRSA-positive, morbidly obese patients with pneumonia.
EUCTR2012-005127-33-BEniversity Ghent20
Active, not recruiting
Phase 1
Clinical trial to evaluate the efficacy, safety and pharmacokinetics profile of nebulized Aztreonam Lysine (AZLI) for prevention of Gram negative pneumonia in heavily colonized mechanically ventilated patientsGram negative pneumonia in heavily colonized mechanically ventilated patientsMedDRA version: 20.0Level: LLTClassification code 10035725Term: Pneumonia NOSSystem Organ Class: 100000004862Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
EUCTR2018-003865-32-ESAlejandro Rodriguez Oviedo - Critical Care Department – Hospital Universitario de Tarragona Joan XXIII20
Not yet recruiting
Not Applicable
Clofazimine and moxifloxacin PK, safety, and AccepTAbiLitY for paediatric TB treatment (CATALYST)
PACTR202012756409365Stellenbosch University36